Intimation under regulation 30- Update on scheme of Amalgamation
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 01 Aug 2026, 01:50 PM IST · BSE ID: 66d423b1-4ea4-4c4a-a953-e65cd28ec1b3
View Original BSE Filing (PDF)
💡
In Simple Terms
Orchid Pharma issued over 4.45 crore new shares to complete its merger with Dhanuka Laboratories.
🤖 AI Summary
- Orchid Pharma Board approved allotment of 4,45,86,052 equity shares to Dhanuka Laboratories shareholders.
- Shares of Rs. 10 each were allotted pursuant to the scheme of amalgamation with Dhanuka Laboratories Limited.
- Record date for eligible Dhanuka Laboratories shareholders was July 23, 2026.
- Paid-up share capital increased to Rs. 59,88,52,000 after allotment and cross-holding cancellation.
- New equity shares will be listed on BSE and NSE, ranking pari-passu with existing shares.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total equity shares allotted
4,45,86,052 equity shares
Face value per share
Rs. 10 each
Record Date for Allotment
July 23, 2026
Post-allotment paid-up share capital
Rs. 59,88,52,000
Total shares post-allotment
5,98,85,200 shares
🏢 How This Affects the Company
The completion of the share allotment solidifies the amalgamation of Dhanuka Laboratories Limited into Orchid Pharma, integrating its operations and assets.
The paid-up share capital of Orchid Pharma has increased to Rs. 59,88,52,000, reflecting the issuance of new equity shares as part of the merger consideration.
👥 What This Means For Shareholders
✅
Action Required
Shareholders of Orchid Pharma Limited are not required to take any action.
👤
Who Is Affected
Shareholders of Dhanuka Laboratories Limited as on record date July 23, 2026, will receive 4,45,86,052 fully paid up equity shares of Orchid Pharma Limited.
🔍
Management Signal
The decision to approve and allot shares indicates management's commitment to completing the amalgamation as per the scheme approved earlier.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Listing approval of new shares on BSE and NSE
Trading commencement of new shares on exchanges
Consolidated financial results for periods post-merger
LOW RISK
This filing marks the completion of a planned corporate action, reducing execution uncertainty.
💡 Investor Takeaway
Orchid Pharma has completed the share allotment for the Dhanuka Laboratories merger, issuing 4,45,86,052 equity shares of Rs. 10 each. The paid-up share capital is now Rs. 59,88,52,000, confirming the final stage of the amalgamation.
⚖️ Strengths & Concerns
✅ Positives
- Completion of share allotment for Dhanuka Laboratories merger finalizes the amalgamation process, integrating business operations.
- New equity shares issued rank pari-passu with existing shares, ensuring equal rights for all shareholders post-merger.
📅 Company Track Record
Orchid Pharma completed its merger with Dhanuka Laboratories, effective July 10, 2026, following NCLT sanction on June 05, 2026. A record date of July 23, 2026, was set for share allotment to Dhanuka Laboratories shareholders.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
How many equity shares did Orchid Pharma allot for the Dhanuka Laboratories merger?
Orchid Pharma allotted 4,45,86,052 fully paid-up equity shares of Rs. 10 each for the scheme of amalgamation.
What is Orchid Pharma's paid-up share capital after this allotment?
Subsequent to this allotment and cancellation of cross-holding, Orchid Pharma's paid-up share capital is Rs. 59,88,52,000, divided into 5,98,85,200 shares.
When was the record date for eligible Dhanuka Laboratories shareholders?
The record date for eligible shareholders of Dhanuka Laboratories Limited to receive Orchid Pharma shares was July 23, 2026.
Will the newly allotted shares be listed for trading?
Yes, the newly allotted shares are proposed to be listed and traded on BSE Limited and National Stock Exchange of India Limited.
Questions based on this BSE filing only. For information purposes.